|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 四联疗法联合口腔洁治根除消化性溃疡合并幽门螺杆菌感染的疗效研究显示文摘目的探讨四联疗法联合口腔洁治根除消化性溃疡合并幽门螺杆菌(helicobacter pylori,Hp)感染初治者的疗效。方法 246例合并胃及口腔Hp感染初治消化性溃疡者采用随机数字表法随机分入对照组和试验组。对照组123例患者予泮托拉唑+胶体果胶铋+克拉霉素+阿莫西林四联疗法治疗;试验组123例患者在对照组基础上另外给予口腔洁治处理。两组患者均完成2周药物治疗。治疗结束后4周对两组患者胃及口腔Hp根除情况进行评估。治疗结束后随访1年,评估两组患者胃及口腔Hp感染复发率。结果治疗结束4周时,试验组和对照组胃Hp根除率分别为91.06%和78.86%,差异有统计学意义(P<0.05)。试验组口腔Hp根除率分67.48%高于对照组44.72%(P<0.05)。随访结束时,试验组和对照组胃Hp感染复发率分别为24.11%和40.21%,差异有统计学意义(P<0.05)。试验组口腔Hp感染复发率41.96%低于对照组74.23%(P<0.05)。结论口腔洁治可提高四联疗法根除消化性溃疡患者胃和口腔Hp的临床疗效,减少胃和口腔Hp感染复发率。 | 张雪莲 王一平 吴维宇 何峰 | 2017 | 成都医学院学报2017，12，5： | 28 |
| 2 | 序贯疗法治疗幽门螺杆菌阳性消化性溃疡的临床观察显示文摘[目的]对比研究序贯疗法与三联疗法治疗幽门螺杆菌(Hp)阳性消化性溃疡的疗效。[方法]将100例幽门螺杆菌阳性消化性溃疡患者随机分成序贯疗法组与三联疗法组,每组50例,治疗10d后比较2组的疗效。[结果]2组治疗前后及复查结果比较差异均有统计学意义(P<0.05);治疗后,序贯疗法组Hp根除率高于三联疗法组,差异有统计学意义(P<0.05)。[结论]从不良反应、患者的经济承担能力及依从性等方面比较,序贯疗法治疗幽门螺杆菌阳性消化性溃疡优于三联疗法。 | 陈黎 刘永爵 龚益清 | 2014 | 中国中西医结合消化杂志2014，22，10： | 14 |
| 3 | 幽门螺旋杆菌感染与胃癌发病及防治相关性的研究进展显示文摘幽门螺旋杆菌在胃部疾病的发病过程中起到重要作用,是胃部疾病演进和发展的重要因素之一。随着胃癌患者幽门螺旋杆菌阳性检出率的不断提高,人们对于胃癌与幽门螺旋杆菌的相关性研究也得到了进展,同时在临床应用中根除幽门螺旋杆菌对胃癌的治疗和预防的作用也得到了一定的研究。本文就近些年相关文献进行归纳,探讨幽门螺旋杆菌与胃癌发病的相关性及其临床治疗状况。 | 豆传辉 | 2018 | 甘肃科技2018，34，11： | 14 |
| 4 | 治疗幽门螺杆菌感染的研究进展显示文摘幽门螺杆菌(Hp)的治疗是临床较为棘手的问题,标准三联疗法的根除率已降至80%或更低,其疗效下降可能与Hp耐药株日益增多相关。含铋四联疗法、序贯疗法、伴同疗法和混合疗法均优于标准三联疗法。在上述方法失败后,可考虑使用含铋四联疗法(未曾使用铋剂时)或喹诺酮三联疗法的二线治疗方案。三线治疗主要根据药敏结果及经验指导治疗。总之,临床医师应当根据具体情况,规范合理地进行抗Hp治疗。 | 张红 李旺泉 欧阳潭 | 2013 | 医学综述2013，19，2： | 14 |
| 5 | 幽门螺杆菌感染与胃癌发生显示文摘幽门螺杆菌(Hp)是一种定植于宿主胃黏膜上皮细胞层的、微需氧、螺旋状革兰阴性杆菌。1984年罗宾·沃伦和巴里·马歇尔首次培养并鉴定了Hp,并明确Hp是胃炎和消化性溃疡主要的病原菌,与胃癌和胃B细胞黏膜相关淋巴组织(MALT)淋巴瘤的发生相关。1994年国际癌症研究机构(IARC)将Hp划归为Ⅰ类致癌物质,这个结论在2009年再次由IARC进一步证实。 | 刘炯 李兆申 | 2014 | 中国实用内科杂志2014，34，5： | 13 |
| 6 | 二烯丙基三硫醚对幽门螺杆菌生物膜的杀菌作用显示文摘目的探讨二烯丙基三硫醚(DATS)对幽门螺杆菌生物膜的杀菌作用,进一步研究生物膜耐药的机制。方法微量肉汤法测定药物的最小抑菌浓度,平板培养法构建幽门螺杆菌生物膜的体外模型,XTT法检测药物处理后浮游状态与生物膜状态下的幽门螺杆菌活性,激光共聚焦显微镜观察生物膜深层的细菌状态以及活性变化。结果克拉霉素与DATS对浮游状态的幽门螺杆菌均有良好的杀菌作用;使用不同浓度克拉霉素处理后的幽门螺杆菌生物膜活性明显低于对照组;DATS处理后的幽门螺杆菌生物膜活性下降明显,与对照组和克拉霉素组有统计学差异。结论 DATS对浮游状态和生物膜状态下的幽门螺杆菌均具有良好的杀菌活性,可以为耐药菌临床治疗提供参考。 | 刘伟 于晗 李玉瑭 刘旭静 李雯 单玉群 孙允东 周亚滨 | 2013 | 山东大学学报(医学版)2013，51，10： | 12 |
| 7 | Helicobacter pylori:Future perspectives in therapy reflecting three decades of experience显示文摘The rising prevalence of antibiotic resistance has created a need to reassess the established Helicobacter pylori(H.pylori)eradication protocols,and to develop new ones.Various bacterial and host factors are evaluated,and their contribution to eradication failure is estimated.For a long time being considered the cornerstone eradication scheme,the standard triple therapy has been replaced with novel,more efficient regimens,namely sequential and concomitant,along with the emergence of a new design of bismuth quadruple therapy.A rescue levofloxacin based regimen has overcome the fear of therapy failure due to higher prevalence of dual resistant(clarithromycin and metronidazole)H.pylori.Culture-free and efficient susceptibility test are reestablishing the concept of tailored therapy,making eradication success close to originally desirable rates.Alleviating therapy side effects and improving patient compliance are as important as choosing appropriate eradication schemes,so various probiotic compound supplements are taken into consideration.Finally,we summarize the emerging efforts and obstacles in creating efficientH.pylori vaccine. | Tajana Filipec Kanizaj Nino Kunac | 2014 | World Journal of Gastroenterology2014，20，3： | 10 |
| 8 | 抗幽门螺杆菌治疗在肿瘤化疗止吐中的作用研究显示文摘目的:评估抗幽门螺杆菌(Helicobacter pylori,HP)治疗及联合常规止吐药物对肿瘤患者化疗所致胃肠道不良反应的疗效。方法:2010年1月至2011年1月,共纳入176例患者,其中伴有幽门螺杆菌感染患者86例。将HP感染阳性者随机分为A组和B组。A组43例给予抗幽门螺杆菌联合止吐药物(奥美拉唑20 mg+克拉霉素500 mg+替硝唑500 mg,2次/d,口服7 d;联合托烷司琼5 mg,静脉滴注,1次/d;疗程共4周)治疗,B组43例仅给予止吐药物(托烷司琼5mg,疗程共4周)治疗,两组患者在性别、年龄、临床表现无差别。应用WHO胃肠道反应分度标准进行观测和评价,应用^(14)C-尿素呼气试验评估幽门螺杆菌根除率。结果:接受化疗并伴有幽门螺杆菌感染的患者呕吐程度比未感染者严重,其中Ⅲ~Ⅳ度呕吐(χ~2=21.92,P<0.001),Ⅰ~Ⅱ度呕吐(χ~2=9.73,P<0.01)差异均有统计学意义。联合抗菌治疗患者的恶心、呕吐等症状比常规止吐患者减轻,A组治疗恶心、呕吐的总有效率为81.39%(35/43),明显高于B组的58.14%(25/43),差异有统计学意义(χ~2=4.46,P<0.05)。结论:针对幽门螺杆菌阳性患者给予抗幽门螺杆菌联合常规止吐治疗,可以有效减轻和缓解化疗所致的胃肠道不良反应。 | 朴瑛 刘兆喆 丁震宇 徐龙 郭放 孙庆庆 谢晓冬 | 2012 | 中国肿瘤临床2012，29，22： | 8 |
| 9 | 东台地区幽门螺杆菌多重耐药现状和相关基因突变的分析显示文摘目的分析江苏东台地区幽门螺杆菌(Helicobacter pylori,H. pylori)对左氧氟沙星、克拉霉素、阿莫西林单一耐药和多重耐药的现状,并探讨本地区gyr A、23SrRNA、PBP1基因突变的特征。方法收集江苏东台医院消化科内镜室400例消化性疾病患者的胃粘膜组织标本,从胃黏膜标本分离培养H. pylori;用E条带(epsilometer test,E-test)分别检测H. pylori对左氧氟沙星、克拉霉素、阿莫西林的最低抑菌浓度(minimum inhibitory concentration,MIC);提取H. pylori基因组DNA;PCR扩增gyr A、23SrRNA、PBP1基因片段,并对扩增产物进行测序分析。结果 E-test药敏结果显示,临床分离的70例H. pylori菌株对左氧氟沙星、克拉霉素、阿莫西林3种抗菌药物的单一耐药率分别为41. 4%、31. 4%、1. 4%;双重耐药的H. pylori菌株中,左氧氟沙星+克拉霉素的耐药率最高,为20%;三重耐药率为1. 4%。基因测序结果显示,江苏东台地区gyr A最常见的突变方式为C261A;23SrRNA的突变方式为A2143G;PBP1基因测序结果显示所有菌株均不存在基因突变。结论江苏东台地区H. pylori对左氧氟沙星、克拉霉素的单一耐药率、双重耐药率较高,应根据药物敏感性试验选择有效的抗菌药物,阿莫西林可作为本地区根除治疗方案的一线药物。 | 张薇 吴李培 宣世海 | 2019 | 实用预防医学2019，26，3： | 8 |
| 10 | Advances in gastric cancer prevention显示文摘Gastric cancer is a multifactorial neoplastic pathology numbering among its causes both environmental and genetic predisposing factors. It is mainly diffused in South America and South-East Asia, where it shows the highest morbility percentages and it is relatively scarcely diffused in Western countries and North America. Although molecular mechanisms leading to gastric cancer development are only partially known, three main causes are well characterized: Helicobacter pylori(H. pylori) infection, diet rich in salted and/or smoked food and red meat, and epithelial cadherin(E-cadherin) mutations. Unhealthy diet and H. pylori infection are able to induce in stomach cancer cells genotypic and phenotypic transformation, but their effects may be crossed by a diet rich in vegetables and fresh fruits. Various authors have recently focused their attention on the importance of a well balanced diet, suggesting a necessary dietary education starting from childhood. A constant surveillance will be necessary in people carrying E-cadherin mutations, since they are highly prone in developing gastric cancer, also within the inner stomach layers. Above all in the United States, several carriers decided to undergo a gastrectomy, preferring changing their lifestyle than living with the awareness of the development of a possible gastric cancer. This kind of choice is strictly personal, hence a decisioncannot be suggested within the clinical management. Here we summarize the key points of gastric cancer prevention analyzing possible strategies referred to the different predisposing factors. We will discuss about the effects of diet, H. pylori infection and E-cadherin mutations and how each of them can be handled. | Antonio Giordano Letizia Cito | 2012 | World Journal of Clinical Oncology2012，3，9： | 8 |
| 11 | 改良序贯疗法补救治疗幽门螺旋杆菌感染的临床疗效显示文摘目的:比较铋剂四联组、10 d改良序贯组、14 d改良序贯组补救根除幽门螺旋杆菌(Helicobacter pylori,H.pylori)感染的效果差异.方法:将首次铋剂四联疗法根除H.pylori失败的195例慢性胃炎、消化性溃疡患者,随机分为铋剂四联组、10 d改良序贯组、14 d改良序贯组,每组65例.A组(铋剂四联组)给予雷贝拉唑、阿莫西林、左氧氟沙星、胶体果胶铋;B组(10 d改良序贯组)前5 d予雷贝拉唑、阿莫西林,后5 d予雷贝拉唑、左氧氟沙星、呋喃唑酮;C组(14 d改良序贯组)前7 d予雷贝拉唑、阿莫西林,后7 d予雷贝拉唑、左氧氟沙星、呋喃唑酮.所有患者在疗程结束停药4 wk后行^(14)C尿素呼气试验.记录3组患者药物不良反应.结果:A、B、C组根除率分别为75.4%、89.2%、95.4%,同A组相比,B组根除率(χ~2=0.039,P<0.05)和C组根除率(χ~2=0.001,P<0.05)明显提高,差异有统计学意义.B组高于C组,差异无统计学意义(χ~2=0.188,P>0.05).A组不良反应率为27.7%、B组不良反应率26.2%、C组不良反应率29.2%,差异无统计学意义(P>0.05).结论:对于H.pylori补救治疗,改良序贯疗法疗效更好,且不良反应低,推荐14 d改良序贯疗法作为首选方案之一. | 曾丽妮 练海燕 王文卿 | 2015 | 世界华人消化杂志2015，23，36： | 8 |
| 12 | Eradication of Helicobacter pylori infection:Which regimen first?显示文摘Helicobacter pylori(H.pylori)is a well-known human pathogen that plays an essential role in the pathogenesis of chronic gastritis,peptic ulcer disease,and gastric malignancies.Although H.pylori is susceptible to several antimicrobials,this infection has proven challenging to cure because of the increasing prevalence of bacterial strains that are resistant to the most commonly used antimicrobials,particularly clarithromycin.An effective(i.e.,>90%)first-line therapy is mandatory for avoiding supplementary treatments and testing,and more importantly for preventing the development of secondary resistance.This study reviews the recent literature on first-line therapies forH.pylori.The eradication rates following standard triple therapy(a proton pump inhibitor plus amoxicillin and clarithromycin)for H.pylori infection are declining worldwide.Several first-line strategies have been proposed to increase the eradication rate,including extending the treatment duration to 14 d,the use of a four-drug regimen(bismuth-containing quadruple,sequential,and concomitant treatments),and the use of novel antibiotics,such as fluoroquinolones.However,the ef5ficacy of these regimens is controversial.A first-line eradication regimen should be based on what works best in a defined geographical area and must take into account the prevalence of antimicrobial resistance in that region. | Alessandro Federico Antonietta Gerarda Gravina Agnese Miranda Carmela Loguercio Marco Romano | 2014 | World Journal of Gastroenterology2014，20，3： | 6 |
| 13 | 序贯疗法与传统标准三联疗法治疗幽门螺杆菌感染的Meta分析显示文摘[目的]评价序贯疗法与传统标准三联疗法治疗幽门螺杆菌(Hp)感染的疗效及两者之间发生不良反应的异同。[方法]检索国内常用的电子数据库,纳入比较标准三联疗法与序贯疗法对Hp根除率的随机对照试验,提取选择患者的基本资料、试验研究的质量、Hp根除率以及不良反应发生率等。荟萃综合分析各项研究对该2种疗法的相对危险度(relative risk,RR)及95%可信区间(95%CI)。利用Cochrane协作网风险偏倚评价标准制作漏斗图评价出版偏倚。[结果]8项随机对照临床试验(RCT),共计890例患者符合纳入标准。Meta分析结果显示,序贯疗法较比传统标准三联疗法具有更高的Hp根除率,即具有更高优越性,其中RR=1.23,95%CI:1.16-1.32。2种疗法的不良反应发生率之间差异无统计学意义(P〉0.05)。[结论]序贯疗法比传统标准三联疗法具有更高的Hp根除率,其不良反应发生率亦较传统标准三联疗法偏低,但由于纳入文献质量不高,故仍需要多中心,大样本的高质量的随机对照临床研究,以期做出更为严谨的系统评价。 | 黄瑞 罗伟生 | 2016 | 中国中西医结合消化杂志2016，24，6： | 6 |
| 14 | 抗幽门螺杆菌节拍治疗在防治胃癌化疗致吐中的意义显示文摘目的:探讨抗幽门螺杆菌节拍治疗相对于常规三联抗幽门螺杆菌(HP)治疗在预防胃癌化疗引起迟发性呕吐中的意义。方法:经14C-尿素呼气试验证实HP感染,经免疫组织化学方法确定为中、重度感染的需首次进行双药联合方案化疗的胃癌患者共69例,分为A、B两组。A组(n=33)采用抗HP节拍治疗,即于化疗第1d开始口服奥美拉唑20 mg 2次/d+阿莫西林0.5 g 2次/d+甲硝唑200 mg 1次/d,口服共14d;B组(n=36)于化疗第1d开始口服奥美拉唑20 mg 2次/d+阿莫西林1 g 2次/d+甲硝唑400 mg 2次/d,口服共7d。两组均同时联合第一代5-HT3拮抗剂格拉司琼3 mg 1次/d,且应用时间均相同。治疗前后分别用免疫组织化学方法评价HP感染情况。结果:A组呕吐患者治疗的总有效率为84.85%,明显高于B组55.56%。A组发生延迟性呕吐需解救治疗的占15.15%,B组占44.44%,A组需解救治疗的比例明显低于B组。A组平均完成化疗周期数明显高于B组(4.5个周期vs.3.1个周期),差异均有统计学意义(P<0.05)。与B组相比较,A组患者HP感染程度明显降低(P<0.05)。结论:在化疗同时采用低剂量、2周抗HP节拍治疗与常规剂量1周方案相比较,可明显减轻胃癌合并HP感染患者化疗相关的迟发性呕吐反应,并可显著降低HP感染程度。 | 满莉 孙长青 董禹洋 马文波 刘建 徐宁 付红伟 朴瑛 | 2016 | 中国肿瘤临床2016，43，2： | 5 |
| 15 | Maastricht Ⅳ共识报告有关幽门螺杆菌感染治疗的新策略显示文摘查阅最新的有关文献,根据MaastriacahtⅣ共识报告,结合2012年北京《第七届全国幽门螺杆菌感染会议》的相关资料以及本人的研究和临床经验,写此文献综述供同道参考。 | 徐采朴 | 2013 | 现代消化及介入诊疗2013，18，3： | 5 |
| 16 | 幽门螺杆菌临床治疗进展显示文摘幽门螺杆菌(Hp)感染是最常见感染之一,它能导致多种胃肠道疾病,已成为全球临床关注的焦点。临床一线治疗包括标准三联疗法、含铋四联疗法、序贯疗法、伴随疗法及混合疗法。含铋四联疗法或含左氧氟沙星三联疗法为二线治疗方案。本文综述临床根除Hp的一线及二线治疗研究进展。 | 陆文霞 王建荣 卢洁 周莹群 郭传勇 | 2015 | 世界临床药物2015，36，3： | 4 |
| 17 | Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection显示文摘AIM: To determine the efficacy of our therapeutic strategy for Helicobacter pylori (H. pylori) eradication and to identify predictive factors for successful eradication. METHODS: From April 2006 to June 2010, we retrospectively assessed 2428 consecutive patients (1025 men, 1403 women; mean age 55 years, age range 18-92 years) with gastric histology positive for H. pylori infection referred to our unit for 13-C urea breath test(UBT), after first-line therapy with proton pump inhibitor (PPI) b.i.d. + amoxicillin 1 g b.i.d. + clarithromycin 500 mg b.i.d. for 7 d. Patients who were still positive to UBT were recommended a second-line therapy (PPI b.i.d. + amoxicillin 1 g b.i.d. + tinidazole 500 mg b.i.d. for 14 d). Third choice treatment was empirical with PPI b.i.d. + amoxicillin 1 g b.i.d. + levofloxacin 250 mg b.i.d. for 14 d. RESULTS: Out of 614 patients, still H. pylori-positive after first-line therapy, only 326 and 19 patients respectively rechecked their H. pylori status by UBT after the suggested second and third-line regimens. 'Per protocol' eradication rates for first, second and thirdline therapy were 74.7% (95% CI: 72.7%-76.4%), 85.3% (95% CI: 81.1%-89.1%) and 89.5% (95% CI: 74.9%-103%) respectively. The overall percentage of patients with H. pylori eradicated after two treatments was 97.8% (95% CI: 97.1%-98.4%), vs 99.9% (95% CI: 99.8%-100%) after three treatments. The study found that eradication therapy was most effective in patients with ulcer disease (P < 0.05, P = 0.028), especially in those with duodenal ulcer. Smoking habits did not significantly affect the eradication rate. CONCLUSION: First-line therapy with amoxicillin and clarithromycin produces an H. pylori eradication rate comparable or superior to other studies and secondline treatment can still be triple therapy with amoxicillin and tinidazole. | Giuliana Sereni Francesco Azzolini Lorenzo Camellini Debora Formisano Francesco Decembrino Veronica Iori Cristiana Tioli Maurizio Cavina Francesco Di Mario Giuliano Bedogni Romano Sassatelli | 2012 | World Journal of Gastroenterology2012，18，33： | 4 |
| 18 | Management of Helicobacter pylori infection in Latin America: A Delphi technique-based consensus显示文摘AIM: To optimize diagnosis and treatment guidelines for this geographic region, a panel of gastroenterologists, epidemiologists, and basic scientists carried out a structured evaluation of available literature.METHODS: Relevant questions were distributed among the experts, who generated draft statements for consideration by the entire panel. A modified three-round Delphi technique method was used to reach consensus. Critical input was also obtained from representatives of the concerned medical community. The quality of the evidence and level of recommendation supporting each statement was graded according to United States Preventive Services Task Force criteria.RESULTS: A group of ten experts was established. The survey included 15 open-ended questions that were distributed among the experts, who assessed the articles associated with each question. The levels of agreement achieved by the panel were 50% in the first round, 73.3% in the second round and 100% in the third round. Main consensus recommendations included:(1) when available, urea breath and stool antigen test(HpSA) should be used for non-invasive diagnosis;(2) detect and eradicate Helicobacter pylori(H. pylori) in all gastroscopy patients to decrease risk of peptic ulcer disease, prevent o retard progression in patients with preneoplastic lesions, and to prevent recurrence in patients treated for gastric cancer;(3) further investigate implementation issues and health outcomes of H. pylorieradication for primary prevention of gastric cancer in high-risk populations;(4) prescribe standard 14-d triple therapy or sequential therapy for first-line treatment;(5) routinely assess eradication success post-treatment in clinical settings; and(6) select second- and third-line therapies according to antibiotic susceptibility testing.CONCLUSION: These achievable steps toward better region-specific management can be expected to improve clinical health outcomes. | Antonio Rollan Juan Pablo Arab M Constanza Camargo Roberto Candia Paul Harris Catterina Ferreccio Charles S Rabkin Juan Cristóbal Gana Pablo Cortés Rolando Herrero Luisa Durán Apolinaria García Claudio Toledo Alberto Espino Nicole Lustig Alberto Sarfatis Catalina Figueroa Javier Torres Arnoldo Riquelme | 2014 | World Journal of Gastroenterology2014，20，31： | 2 |
| 19 | 序贯疗法与新四联疗法根治Hp感染的效果对比分析显示文摘目的临床对比序贯疗法及新四联疗法根治幽门螺杆菌(Helicobacter pylori,Hp)感染的效果。方法 Hp患者平分为序贯组和新四联组,各43例,序贯组采用10d序贯疗法,1~5d、6~10d分别给以奥美拉唑、阿莫西林和奥美拉唑、克拉霉素和甲硝唑治疗;新四联组给以奥美拉唑、阿莫西林、克拉霉素、胶体果胶秘治疗,疗程均为7d,均1日2次;两组患者Hp根除率由胃镜和13C尿素呼气试验检测;记录各组患者溃疡愈合、症状缓解情况以及不良反应例数。结果序贯组患者Hp根除率、溃疡愈合有效率分别达90.70%、88.37%,与标新四联组相比存在显著性差异(P〈0.05);序贯组患者疼痛缓解率达93.02%,症状缓解时间等指标较短,明显优于新四联组(P〈0.05);序贯组不良反应率仅为11.63%,与新四联组比较有显著性差异(P〈0.05)。结论 10d序贯疗法治疗Hp患者可取得更好的治疗效果,并降低不良反应率,达到临床治疗理想疗效。 | 夏瑞丰 梁海君 马民华 赵敬茹 朱昌鹏 王熠 | 2015 | 海峡药学2015，27，1： | 1 |
| 20 | 胃黏膜“血清学活检”在健康体检中的应用显示文摘随着健康管理理念的普及,健康体检越来越被大众所接受。因此,寻找一种灵敏、准确、无创的早期检测方法,用于包括胃癌在内的胃疾病的人群普查及其健康管理具有重要意义。本文主要探讨胃黏膜'血清学活检'作为胃疾病筛查指标在体检人群健康管理中预防及早诊的应用价值。 | 吴叶枫 赵欢 景晶晶 袁媛 | 2015 | 胃肠病学和肝病学杂志2015，24，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员